Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-03526299 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| PF-03526299 1.396 mg | EXPERIMENTAL | - |
| PF-03526299 4mg | EXPERIMENTAL | - |
| PF-03526299 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Fluticasone propionate | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-03526299 | DRUG | dry powder for inhalation, 1.396 mg, BID for 14 days |
| Placebo | DRUG | Inhaled, two doses 4 hours apart |
| Fluticasone propionate | DRUG | Inhaled |
Inclusion Criteria: * Healthy male subjects and females of non-childbearing potential between the ages of 21 and 55 years. * Body Mass Index (BMI) of 17.5 to 30.5 kg/m\^2; and a total body weight \>50 kg (110 lbs). * Subjects who had a normal chest X-ray in the previous 6 months prior to Screening ...
PF-03526299 is an investigational small molecule being studied for respiratory conditions, specifically asthma. It was evaluated in a Phase 1 trial in asthmatic subjects to assess its effect on lung function following an allergen challenge. It has also been studied in healthy volunteers for safety and tolerability.
PF-03526299 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is in Phase 1 clinical development.
PF-03526299 is in Phase 1 clinical development. It has completed two Phase 1 trials, one in asthmatic subjects and one in healthy volunteers. The drug is investigational and has not been approved by regulatory authorities.
PF-03526299 has completed two Phase 1 trials. NCT00877539 assessed its effect on lung function after an allergen challenge in 29 asthmatic subjects in the United Kingdom. NCT00990756 evaluated safety and tolerability of different doses in 24 healthy adult volunteers in Singapore.
No alternative names for PF-03526299 have been disclosed. The drug is identified solely by its Pfizer development code, PF-03526299, in clinical trial registries and available information.